Familial Pancreatic Cancer PROPHilation Program in Italy (PROPH-ITA)

Associazione Italiana per lo Studio del Pancreas

Status: Enrolling

Conditions: Candidates for Hereditary Pancreatic Cancer Testing

Treatments: Genetic: Saliva swab testing

Study type: Interventional

Funder types: Other

Identifiers

NCT05724992

PROPH-ITA

Details and patient eligibility

About

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.

Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.

Up to 3,000 participants will be enrolled in this study.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Being enrolled on the IRFARPC registry
• Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
• Willingness to participate in saliva-swab-based genetic testing

Exclusion criteria

• Already known genetic mutation

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3,000 participants in 1 patient group

Saliva testing swab

Other group

Description:

Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing

Treatment:

Genetic: Saliva swab testing